Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is a cluster randomized trial on effectiveness of different modalities of Single Double
Dose of Rifampicin Post-Exposure Prophylaxis (SDDR-PEP) for leprosy in the Comoros (Anjouan
and Mohéli) and Madagascar.
The study aims to identify which approach to the selection of contacts for post exposure
prophylaxis is most effective to reduce incident leprosy, and to Interrupt ongoing
transmission from asymptomatic persons in the process of developing multibacillary leprosy.
Phase:
Phase 3
Details
Lead Sponsor:
Institute of Tropical Medicine, Belgium
Collaborators:
Centre d'Infectiologie Charles Mérieux Centre d’Infectiologie Charles Mérieux Damien Foundation Fondation Raoul Follereau Genoscreen Instituto Fernandes Figueira L'Institut National de la Santé et de la Recherche Médicale Leiden University Medical Center